Frank Shannon

Frank Shannon has a diverse work experience in the pharmaceutical and medical industry. Frank is currently serving as the Vice President of Clinical Development and Regulatory Affairs at Sernova Corp. Prior to this, they worked as an Advisor in Residence at Temerty Faculty of Medicine, University of Toronto - Health Innovation Hub (H2i) starting from November 2016. From January 2020 to July 2021, they held the position of VP Clinical, Regulatory, and Quality at Ripple Therapeutics. Frank also worked at Interface Biologics as the VP of Clinical Development, Regulatory Affairs, and Quality from May 2016 to July 2021. Frank served as the Director of Quality at Baxter Corporation from September 2014 to May 2016. Before that, Frank worked at St. Jude Medical as the Director of Regulatory and Quality from June 2011 to August 2014. Frank also served as the Vice President of Clinical and Regulatory Affairs at Interface Biologics from February 2009 to June 2011. In addition, they have experience working as an Associate Director of Global Late Phase Research at i3 Innovus from February 2008 to February 2009, and as the Director of Clinical Development and Outcomes Research at Occulogix, Inc. from December 2006 to February 2008. Frank's early work experience includes serving as a Medical Scientific Advisor in Vascular Medicine at Boehringer Ingelheim Canada from May 2001 to December 2006.

Frank Shannon completed their undergraduate education at Brock University from 1984 to 1990, obtaining a degree in HB.Psych with a focus on Psychology and Neuroscience. Following this, from 2000 to 2009, they pursued a Master of Science Program in Epidemiology at the University of Toronto, where they completed coursework and thesis work in that field.